Ralph Lauren Slides on Q1 Figures
Ralph Lauren Corporation (NYSE:RL) shares began Thursday lower. The company, a global leader in the design, marketing, and distribution of luxury lifestyle products, today reported earnings per diluted share of $3.52, up 35% to prior year on a reported basis and $3.77, up 40% on an adjusted basis, excluding restructuring-related and other net charges, for the first quarter of Fiscal 2026. This compared to earnings per diluted share of $2.61 on a reported basis and $2.70 on an adjusted basis, excluding restructuring-related and other net charges for the first quarter of Fiscal 2025."What we stand for -- aspiration, optimism, individuality and authenticity -- inspires people in every corner of the world," said Lauren. "And we are bringing these values to life and inviting people to step into their dreams in new and powerful ways -- from our first-ever fashion presentation in Shanghai this April to our MLB World Tour™ Tokyo Series activations and our Women's Polo presentation in Paris.""We delivered strong first quarter results across geographies, channels and consumer segments," said CEO Patrice Louvet. "While we continue to approach the current global operating environment with prudence, we are encouraged by the broad-based strength in our brand and our businesses as we execute on our long-term strategic priorities — including recruiting new and younger consumers, strengthening our core and high-potential categories, and developing our key city ecosystems in each region."RL shares crumbled $22.85, or 7.6%, to $280.11
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


